Home / Infection Control / Rensair named on Newsweek’s list of Best Infection Prevention Products 2021

Rensair named on Newsweek’s list of Best Infection Prevention Products 2021

Air purification specialist Rensair has been included in Newsweek’s list of Best Infection Prevention Products 2021. Newsweek, in partnership with the Leapfrog Group, an independent nonprofit that evaluates health care quality, compiles and publishes an ongoing series of ratings for healthcare facilities and products.

The Rensair hospital-grade air purifier is included within the ‘Lighting Disinfectants’ category. To make the list, a selection committee evaluated the product using four criteria: effectiveness, safety (to both patients and healthcare workers), successful real-world implementation and the stability of the company (to support future implementations).

Leapfrog also evaluated the quality of research studies demonstrating the product’s effectiveness by looking at reproducibility, closeness between lab data/results and real-world application of the data/results, and closeness of fit between the choice of test or method of testing and what was being tested for.

Christian Hendriksen, Co-founder and CEO of Rensair commented: “We are proud to be included in this evidence-based list of infection prevention products that   evaluates real-world implementation. Safe, breathable air has never been more important, but Covid-19 is not the only threat. Hospitals also need protection against the rise in multidrug-resistant, airborne bacterial infections, which claim at least 700,000 lives per year worldwide and are projected to cause 10 million deaths per year by 2050.”

Rensair’s patented technology was developed in Denmark to meet the strict air quality requirements of Scandinavian hospitals. Its efficacy is documented by several independent scientific laboratories, including Eurofins, Norconsult, and Oslo University Hospital. Tests conducted by the Danish Technological Institute in March 2021, which used aerosolised MS2 bacteriophages as a proxy for Covid-19, further proved its efficiency at capturing and inactivating the Coronavirus family of viruses.

On the back of these credentials, Rensair’s technology has been adopted by doctor and dental practices, care homes and hospitals worldwide, including several NHS trusts in the UK. With operations in the UK, Europe, the USA and Asia, the company has recently expanded its client base beyond the health sector, enabling both public and private organisations to benefit from a safer working environment. Clients include multinationals, manufacturers, educational establishments, and hospitality venues.

rensair.com

About Sarah OBeirne

Leave a Reply